Molecular and Cellular Mechanisms of Ectodomain Shedding
Article first published online: 19 MAY 2010
Copyright © 2010 Wiley-Liss, Inc.
The Anatomical Record
Volume 293, Issue 6, pages 925–937, June 2010
How to Cite
Hayashida, K., Bartlett, A. H., Chen, Y. and Park, P. W. (2010), Molecular and Cellular Mechanisms of Ectodomain Shedding. Anat Rec, 293: 925–937. doi: 10.1002/ar.20757
- Issue published online: 19 MAY 2010
- Article first published online: 19 MAY 2010
- Manuscript Accepted: 8 FEB 2008
- Manuscript Received: 29 DEC 2007
- National Institutes of Health. Grant Numbers: HL69050, HL73725,, HL81474
- Mizutani Foundation. Grant Number: 070028
- ectodomain shedding;
- lung injury;
- host defense
- Top of page
- MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- LITERATURE CITED
The extracellular domain of several membrane-anchored proteins is released from the cell surface as soluble proteins through a regulated proteolytic mechanism called ectodomain shedding. Cells use ectodomain shedding to actively regulate the expression and function of surface molecules, and modulate a wide variety of cellular and physiological processes. Ectodomain shedding rapidly converts membrane-associated proteins into soluble effectors and, at the same time, rapidly reduces the level of cell surface expression. For some proteins, ectodomain shedding is also a prerequisite for intramembrane proteolysis, which liberates the cytoplasmic domain of the affected molecule and associated signaling factors to regulate transcription. Ectodomain shedding is a process that is highly regulated by specific agonists, antagonists, and intracellular signaling pathways. Moreover, only about 2% of cell surface proteins are released from the surface by ectodomain shedding, indicating that cells selectively shed their protein ectodomains. This review will describe the molecular and cellular mechanisms of ectodomain shedding, and discuss its major functions in lung development and disease. Anat Rec, 293:925–937, 2010. © 2010 Wiley–Liss, Inc.
MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- Top of page
- MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- LITERATURE CITED
Ectodomain shedding affects a diverse list of molecules, including cytokines, growth factors, cell adhesion molecules, enzymes, and many more (Table 1). There are several common mechanistic features in the ectodomain shedding of cell surface molecules (Fig. 1). Most show little basal shedding, but are dramatically induced upon cellular activation. Phorbol esters induce shedding of the majority of protein ectodomains, suggesting that protein kinase C (PKC) is one of the key regulators. Indeed, chemically mutagenized CHO cells that are defective in PMA-induced TGFα shedding are also defective in phorbol 12-myristate 13-acetate (PMA)-induced shedding of several other transmembrane proteins, such as TNFα, amyloid precursor protein (APP), and L-selectin (Arribas and Massague,1995; Arribas et al.,1996). Furthermore, inhibitors of protein tyrosine kinases (PTKs; Fitzgerald et al.,2000; Gutwein et al.,2000) and MAP kinases inhibit shedding (Fan and Derynck,1999; Fitzgerald et al.,2000), whereas agonists of G-protein coupled receptors (GPCRs), calcium ionophores, and ceramide induce shedding of a number of molecules (Porteu and Nathan,1990; Madge et al.,1999; Fitzgerald et al.,2000; Lemjabbar and Basbaum,2002; Matthews et al.,2003; Mortier et al.,2004). These data illustrate that several intracellular signaling pathways regulate ectodomain shedding and, consistent with these observations, agonists that activate these signaling pathways, such as growth factors, cytokines, and bacterial toxins, have been shown to enhance shedding (Subramanian et al.,1997; Jones et al.,1999; Yabkowitz et al.,1999; Fitzgerald et al.,2000; Park et al.,2000,2004; Chen et al.,2007). In addition, peptide hydroxamate inhibitors of metalloproteinases inhibit the shedding of most cell surface proteins, with the exception of glycosylphosphatidylinositol (GPI)-anchored proteins, which are primarily shed by phospholipases. Collectively, these data indicate that ectodomain shedding is generally regulated by outside-in signaling, which in turn modulates substrate cleavage by metalloproteinase sheddases at the cell surface.
|Cell adhesion molecules||Growth factors and receptors||Immunomodulators and receptors|
|Collagen XIII (Vaisanen et al.,2004)||Amphiregulin (Sahin et al.,2004)||Betaglycan (Velasco-Loyden et al.,2004)|
|Collagen XVII (Franzke et al.,2002)||Betacellulin (Sahin et al.,2004)||CD23 (Letellier et al.,1990)|
|Collagen XXIII (Veit et al.,2007)||CHL1 (Naus et al.,2004)||CD30 (Hansen et al.,2004)|
|E-Cadherin (McGuire et al.,2003)||c-Met (Nath et al.,2001)||CD40 (Contin et al.,2003)|
|N-Cadherin (Reiss et al.,2005)||EGF (Sahin et al.,2004)||CD93 (Bohlson et al.,2005)|
|VE-Cadherin (Herren et al.,1998)||EGFRs (Lin and Clinton,1991)||CD223 (Li et al.,2007)|
|CD44 (Bazil and Strominger,1994)||Ephrins (Hattori et al.,2000)||CSF-1 (Tuck et al.,1994)|
|Glycoprotein V (Rabie et al.,2005)||Epiregulin (Sahin et al.,2004)||CXCL16 (Matloubian et al.,2000)|
|Glycoprotein VI (Bergmeier et al.,2004)||FGFR1 (Hanneken et al.,1994)||Fas (Cheng et al.,1994)|
|ICAM1 (Becker et al.,1991)||GHR (Alele et al.,1998)||FasL (Tanaka et al.,1998)|
|L1 (Beer et al.,1999)||HB-EGF (Suzuki et al.,1997)||Fractalkine (Garton et al.,2001)|
|NCAM (Hubschmann et al.,2005)||HGF (Mizuno et al.,1994)||GM-CSFR (Prevost et al.,2002)|
|Nectin-1α (Tanaka et al.,2002)||KL-1 (Pandiella et al.,1992)||IL-1RII (Cui et al.,2003b)|
|Nectin-4 (Fabre-Lafay et al.,2005)||Neuregulin (Sahin et al.,2004)||IL-2R (Junghans and Waldmann,1996)|
|Neuroglycan C (Shuo et al.,2007)||NgR (Ahmed et al.,2006)||IL-6R (Croucher et al.,1999)|
|NG2 (Asher et al.,2005)||NTR(p75) (Weskamp et al.,2004)||IL-15R (Mortier et al.,2004)|
|PECAM-1 (Ilan et al.,2001)||Osteoactivin (Furochi et al.,2007)||LAR (Streuli et al.,1992)|
|E-selectin (Wyble et al.,1997)||TGFα (Wong et al.,1989)||LOX-1 (Hayashida et al.,2005)|
|L-selectin (Migaki et al.,1995)||TIE1 (Marron et al.,2007)||RANKL (Hikita and Tanaka,2007)|
|P-selectin (Semenov et al.,1999)||TSHR (Couet et al.,1996)||TNFα (Black et al.,1997)|
|SHPS-1 (Ohnishi et al.,2004)||TNFRI, TNFRII (Porteu and Nathan,1990)|
|Syndecan-1 (Subramanian et al.,1997)||TRANCE (Lum et al.,1999)|
|Syndecan-2 (Fears et al.,2006)||TREM1 (Gomez-Pina et al.,2007)|
|Syndecan-3 (Reizes et al.,2001)|
|Syndecan-4 (Subramanian et al.,1997)||Enzymes||Others|
|VCAM-1 (Singh et al.,2005)||ACE (Sadhukhan et al.,1999)||APP (Esch et al.,1990)|
|BACE1 (Hussain et al.,2003)||Delta (LaVoie and Selkoe,2003)|
|MT1-MMP (Osenkowski et al.,2004)||Jagged (LaVoie and Selkoe,2003)|
|Leptin receptor (Ge et al.,2002)|
|MUC-1 (Thathiah et al.,2003)|
|Notch (Pan and Rubin,1997)|
|Transferrin receptor (Chitambar et al.,1991)|
Extracellular and Intracellular Regulators of Shedding
Ectodomain shedding can be induced by various stimuli, such as phorbol esters (Arribas and Massague,1995; Arribas et al.,1996), cytokines (Becker et al.,1991; Wyble et al.,1997; Jones et al.,1999; Yabkowitz et al.,1999; Singh et al.,2005), growth factors (Subramanian et al.,1997; Fitzgerald et al.,2000; Mortier et al.,2004), pervanadate (Reiland et al.,1996; Gutwein et al.,2000; Kaup et al.,2002; Le Gall et al.,2003; Velasco-Loyden et al.,2004), ceramide (Fitzgerald et al.,2000; Walev et al.,2000; Matthews et al.,2003), cellular stress (Fitzgerald et al.,2000), calcium ionophores (Dethlefsen et al.,1998; Reiss et al.,2005), and bacterial toxins (Walev et al.,1996; Park et al.,2000,2004; Chen et al.,2007). Some of these globally activate shedding of many cell surface proteins, whereas others specifically stimulate shedding of certain protein ectodomains. Rapid induction of shedding by phorbol esters is one of the hallmark features of ectodomain shedding and, accordingly, several PKC isozymes regulate shedding. For example, PKCϵ is required for TNFα shedding (Wheeler et al.,2003). PKCδ regulates heparin binding (HB) epidermal growth factor (EGF)-like shedding (Izumi et al.,1998), whereas PKCδ and PKCη are involved in IL-6 receptor (IL-6R) shedding (Thabard et al.,2001). These findings indicate that different substrates require distinct PKC isozymes for its shedding regulation, but the underlying basis of this specificity is not understood.
Several studies indicate that PTKs are also positive regulators of ectodomain shedding (Subramanian et al.,1997; Fitzgerald et al.,2000; Gutwein et al.,2000; Phong et al.,2003). Pervanadate, a general and potent inhibitor of protein tyrosine phosphatases, enhances the shedding of the adhesion molecule L1, APP, syndecan-1 and -4, and angiotensin converting enzyme (ACE), among others, and PTK inhibitors inhibit the shedding of these surface molecules (Subramanian et al.,1997; Fitzgerald et al.,2000; Gutwein et al.,2000; Park et al.,2000; Phong et al.,2003). Precisely how kinases modulate shedding has yet to be clearly defined, but current data suggest that both PTKs and PKCs do not enhance shedding by phosphorylating the substrate. For example, pervanadate-induced ACE shedding does not require the cytoplasmic domain of ACE (Santhamma et al.,2004). Similarly, deletion of the cytoplasmic tails of IL-6R (Mullberg et al.,1994) and TNFα receptor II (TNFRII) (Crowe et al.,1993) does not affect shedding of their ectodomains by PMA, despite the fact that the cytoplasmic domains of these cytokine receptors are phosphorylated by PMA stimulation. Antibody crosslinking induces the shedding of L-selectin by sequestering L-selectin to a lipid raft membrane compartment where L-selectin is highly Tyr phosphorylated (Phong et al.,2003), but there is no evidence that Tyr phosphorylation of the L1 cytoplasmic domain is required for shedding. Consistent with these data, the cytoplasmic tail of L1 is not Tyr phosphorylated in PMA-induced shedding (Gutwein et al.,2000), and Tyr residues of the L1 cytoplasmic domain are dispensable in hepatocyte growth factor (HGF)-induced shedding (Heiz et al.,2004). Shedding of APP induced by pervanadate and PMA stimulation is blocked by PTK inhibitors, but the cytoplasmic domain of APP is not Tyr phosphorylated by pervanadate or PMA stimulation (Slack et al.,1995). Further, PMA and several other inducers of HB-EGF shedding induce Ser phosphorylation of the HB-EGF cytoplasmic domain, but mutation of the phosphorylated Ser residues has no effect on HB-EGF shedding (Wang et al.,2006). Collectively, these data indicate that PKCs and PTKs phosphorylate components other than the substrate in enhancing ectodomain shedding.
The cytoplasmic domain of substrates, however, can affect ectodomain shedding through interactions with intracellular modifiers. Calmodulin binds to the cytoplasmic domain of L-selectin and ACE in a constitutive manner, and its dissociation induced by calmodulin kinase inhibitors or PMA activates shedding, indicating that calmodulin is a negative regulator of L-selectin and ACE shedding (Kahn et al.,1998; Matala et al.,2001). In fact, calmodulin kinase inhibitors and calcium ionophores also induce the shedding of CD44, EGF, betacellulin, N-cadherin, and IL-6R (Nagano et al.,2004; Reiss et al.,2005; Sanderson et al.,2005). These data suggest that regulation of shedding by calmodulin and calcium is a common mechanism. The APP homolog APLP1 binds to APP and interferes with endocytosis of APP through a conserved NPTY motif in the cytoplasmic domain and increases APP shedding (Neumann et al.,2006). The carboxyl terminus Val in the cytoplasmic domain of TGFα is required for its shedding induced by various stimuli (Bosenberg et al.,1992), suggesting that structural features of the TGFα cytoplasmic tail is essential for its interaction with intracellular regulators of shedding. Available data also implicate actin-binding proteins of the ERM family in the regulation of shedding. Ezrin is bound to the cytoplasmic tail of L-selectin in both resting and PMA-stimulated lymphocytes, but only moesin binding to the L-selectin cytoplasmic tail is associated with the activation of shedding (Ivetic et al.,2002). Importantly, mutation of the Ezrin/Radixin/Moesin (ERM) binding site interferes with L-selectin shedding, suggesting that ERM interactions are critical (Ivetic et al.,2004). Furthermore, retention of substrates in intracellular compartments can negatively influence shedding at the cell surface. Santhamma et al. showed that the molecular chaperone, immunoglobulin binding protein (BiP), associates with ACE, and that BiP overexpression blocks ACE shedding by retaining ACE in the endoplasmic reticulum (ER) (Santhamma and Sen,2000).
In addition to PKC and PTK signaling, other signaling pathways involving ATP (Hubschmann et al.,2005; Sengstake et al.,2006), MAP kinases (Fan and Derynck,1999; Fitzgerald et al.,2000), and GPCRs (Prenzel et al.,1999; Fitzgerald et al.,2000) have been shown to influence ectodomain shedding. Transactivation of the EGF receptor through GPCR stimulation by lysophosphatidic acid, endothelin, thrombin, bombesin, or carbachol has been shown to enhance HB-EGF shedding (Prenzel et al.,1999), and GPCR activation by thrombin-derived peptides induces the shedding of syndecan-1 and -4 (Fitzgerald et al.,2000). Inhibitor studies have shown that MAP kinases are required for the shedding of (i) syndecan-1 and -4 by EGF, thrombin, ceramide, and osmotic stress (Fitzgerald et al.,2000); (ii) IL-6R by PMA (Thabard et al.,2001); (iii) TGFα, TNFα, and L-selectin by growth factors (Fan and Derynck,1999); and (iv) HB-EGF by PMA (Gechtman et al.,1999). In L-selectin shedding, nonsteroidal anti-inflammatory drugs increase the intracellular concentration of ATP, which in turn activates PKC and MAP kinase (Budagian et al.,2003; Sengstake et al.,2006). Altogether, these data suggest that extracellular agonists activate several distinct intracellular signaling pathways that converge to regulate a metalloproteinase-mediated cleavage mechanism at the cell surface.
The first clue to identify the sheddase was provided by the finding that peptide hydroxamate inhibitors of metalloproteinases block the shedding of membrane bound TNFα (Mohler et al.,1994). Subsequently, shedding of the majority of proteins was also found to be inhibited by peptide hydroxamates, and TNFα converting enzyme (TACE) was identified as the TNFα sheddase in 1997 (Black et al.,1997; Moss et al.,1997). TACE is a member of the disintegrin and metalloproteinase (ADAM) family (Schlondorff and Blobel,1999), and is also referred to as ADAM17. TACE/ADAM17 is also a sheddase for other surface molecules, such as TNFRs (Peschon et al.,1998), L-selectin (Peschon et al.,1998), vascular cell adhesion molecule-1 (VCAM-1; Garton et al.,2003), fractalkine (Garton et al.,2001), ErbB-4 (Rio et al.,2000), colony stimulating factor-1 (CSF-1) (Horiuchi et al.,2007b), APP (Buxbaum et al.,1998; Huovila et al.,2005), and the EGF family ligands TGFα (Peschon et al.,1998), HB-EGF (Sunnarborg et al.,2002; Jackson et al.,2003), amphiregulin (Sunnarborg et al.,2002; Sternlicht et al.,2005), and epiregulin (Sahin et al.,2004).
Although TACE/ADAM17 can shed many cell surface proteins, it is not the only sheddase and several proteins that are not shed by TACE/ADAM17 (e.g., ACE, TRANCE, syndecan-1) (Sadhukhan et al.,1999; Fitzgerald et al.,2000; Schlondorff et al.,2001). ADAM9 and ADAM12 shed HB-EGF (Izumi et al.,1998; Asakura et al.,2002), ADAM10 sheds E-cadherin (Maretzky et al.,2005), N-cadherin (Reiss et al.,2005), HB-EGF (Lemjabbar and Basbaum,2002), betacellulin (Horiuchi et al.,2007a), Notch (Pan and Rubin,1997), L1 (Mechtersheimer et al.,2001), APP (Huovila et al.,2005) and CXCL16 (Abel et al.,2004), and ADAM8, ADAM15, and ADAM28 shed CD23, a low affinity IgE receptor (Fourie et al.,2003).
Furthermore, metalloproteinases belonging to the family of matrix metalloproteinases (MMPs) can shed several protein ectodomains. MMP-2 sheds syndecan-2 (Fears et al.,2006), MMP-3 sheds Fas ligand (FasL) (Matsuno et al.,2001) and HB-EGF, MMP7 sheds TNFα (Gearing et al.,1994,1995; Haro et al.,2000), FasL (Powell et al.,1999), HB-EGF (Yu et al.,2002), E-cadherin (Noe et al.,2001; McGuire et al.,2003), β4 integrin (von Bredow et al.,1997), and syndecan-1 (Li et al.,2002), and MMP-9 sheds E-cadherin (Symowicz et al.,2007), ICAM-1 (Fiore et al.,2002), c-kit ligand (Heissig et al.,2002), and syndecan-1 and -4 (Brule et al.,2006). The transmembrane MMP, MMP-14, can mediate the shedding of TRANCE (Schlondorff et al.,2001), CD44, and syndecan-1. In addition, many bacterial pathogens, including Pseudomonas aeruginosa, E. coli, Bacteroides fragilis, Staphylococcus aureus, Streptococcus pyogenes (Group A Streptococcus, GAS), Listeria monocytogenes, Bacillus anthracis, and Streptococcus pneumoniae, express metalloproteinases that shed various inflammatory factors from the host cell surface (Vollmer et al.,1996; Lathem et al.,2003; Grys et al.,2005; Chung et al.,2006; Chen et al.,2007; Leduc et al.,2007; Wu et al.,2007). Thus, many metalloproteinases possess the capacity to function as sheddases. However, ectodomain shedding is likely specific in vivo because the expression of the substrate, sheddase, and extracellular and intracellular regulatory factors are tightly controlled in a spatial and temporal manner.
Examination of the cleavage site sequence of several substrates shed by TACE/ADAM17 indicates that the distance from the plasma membrane and structure of the cleavage site region are more important than the specific sequence in ectodomain shedding. Most mutations in the cleavage site or adjacent residues do not affect the shedding of TGFα (Wong et al.,1989), TNFα (Tang et al.,1996), APP (Sisodia,1992), L-selectin (Migaki et al.,1995), and TNFRI (Brakebusch et al.,1994) by TACE/ADAM17 as long as the overall distance is maintained. However, insertion of amino acids that disrupt the secondary structure (e.g., Pro, Gly) in the juxtamembrane region blocks shedding of L-selectin (Zhao et al.,2001c), TGFα (Brachmann et al.,1989; Wong et al.,1989), APP (Sisodia,1992), TNFRI (Brakebusch et al.,1994), and TNFRII (Herman and Chernajovsky,1998) by TACE/ADAM17. Of the two naturally occurring isoforms of ErbB-4, the isoform with 23 amino acids inserted in the juxtamembrane region is easily shed, but the other one with 13 amino acids is not shed efficiently (Elenius et al.,1997). Further, a mutant construct of APP with deletion of the cleavage site is still cleaved at a different -P1-P′ 1- sequence at exactly the same distance from the membrane as ™-type APP (Maruyama et al.,1991). However, a 14-amino acid sequence of the juxtamembrane domain of APP or TGFα is sufficient to confer shedding susceptibility to betaglycan (Arribas et al.,1997), whereas an 11 amino acid deletion within the juxtamembrane region of APP inhibited its shedding by α secretase (Sisodia et al.,1990). Thus, although the cleavage site is predominantly specified by the distance from the plasma membrane and structure of the cleavage site region, these latter findings suggest that there is some degree of sequence specificity in the shedding of certain substrates.
Trafficking, Modification, and Activation of Sheddases
ADAMs and MMPs are produced as zymogens, and proteolytic removal of the prodomain activates these metalloproteinases. ADAMs typically have a cleavage site in their prodomain for the serine endopeptidases, furin and furin-like proprotein convertase (PC), and several studies have shown that ADAM zymogens are activated through cleavage of the prodomain by furin-like PCs in the trans-Golgi/endosomal compartment (Lum et al.,1998; Loechel et al.,1999; Roghani et al.,1999). Although proteolytic processing by furins is generally constitutive and occurs in intracellular compartments, several studies have shown that furin can process proteins in a specific cellular compartment formed by the fusion of endocytic furin-containing compartments and substrate-containing compartments (Band et al.,2001; Chen et al.,2001). Further, furin can also function at the cell surface as exemplified by its capacity to activate bacterial toxins at the cell surface (Klimpel et al.,1992; Schiavo and van der Goot,2001). More importantly, shedding of several proteins, such as TNFα, Kit ligand-1 (KL-1), KL-2, CD44, and LOX-1, is inhibited by serine proteinase inhibitors (Scuderi,1989; Pandiella et al.,1992; Bazil and Strominger,1994; Robache-Gallea et al.,1995; Murase et al.,2000), and furin-deficient cells are impaired in PKC-dependent shedding of APP (Lopez-Perez et al.,2001). In addition, furin can activate several MMPs (e.g., MMP-14, MMP-15), suggesting that furins may also regulate ectodomain shedding through MMP activation. Alternatively, cells can activate sheddases through specific modifying reactions. Reactive oxygen species induced by PMA activate TACE/ADAM17 through an oxidative attack of the thiol group in the Cys switch, which disrupts the inhibitory effect of the prodomain on the enzymatic activity (Zhang et al.,2001).
Some studies have also shown that intracellular trafficking of sheddases influences ectodomain shedding. For example, PMA treatment induces the translocation of ADAM12 to the cell surface in a PKCϵ-dependent manner (Sundberg et al.,2004). Another study showed that in polarized epithelial cells, ADAM10 is sorted exclusively to the basolateral compartment and this depends on specific Pro residues in the Src homology 3 binding domain (SH3) in the cytoplasmic domain of ADAM10 (Wild-Bode et al.,2006). Interestingly, this SH3 motif is also required for ADAM10-mediated shedding of E-cadherin (Wild-Bode et al.,2006). In addition, ethyl-methane sulfonate-induced CHO mutant cells defective in TACE/ADAM17-dependent ectodomain shedding have impaired trafficking of TACE/ADAM17 from the ER, which interferes with the activation of TACE/ADAM17 by furins (Borroto et al.,2003).
Other means of posttranslationally regulating the expression of sheddases include sequestering the sheddase by internalization to a location where it is either isolated from or in close vicinity to its potential substrates (Jiang et al.,2001; Lafleur et al.,2006) and targeting the sheddase by polarized secretion to specific membrane domains (Galvez et al.,2004; Labrecque et al.,2004). For instance, in Madine Darby canine kidney (MDCK) epithelial cells, EGF is targeted to both the basal and apical membrane compartments, but EGF is predominantly expressed on the apical surface because its sheddase is targeted to the basal surface, and EGF is preferentially cleaved at this site to achieve the polarized expression at the apical surface (Dempsey et al.,1997).
Recruitment and Modification of Substrates
Cells also regulate shedding by targeting the substrate to specific cellular compartments. Cholesterol depletion from cells, which displaces substrates from lipid raft microdomains, induces the shedding of CD30 by TACE/ADAM17 and IL-6 receptor by ADAM10 and TACE/ADAM17 (Matthews et al.,2003; von Tresckow et al.,2004), and antibody-induced clustering induces shedding of CD30 (Hansen et al.,2000), CD44 (Shi et al.,2001), and L-selectin (Phong et al.,2003). Protein–protein interactions between the substrate and modifying proteins also influence shedding. Substrate interactions with signaling molecules, such as PKC, activate shedding by potentially inducing a conformational change in the substrate to facilitate the substrate-sheddase encounter. Binding of ARTS-1 (aminopeptidase regulator of TNFRI shedding) to TNFRI and IL-6R promotes shedding of these cytokine receptors (Cui et al.,2002,2003a). However, although ARTS-1 is an active enzyme, it has no sheddase activity, suggesting that it binds to the substrate and induces a conformational change. In addition, Nichols et al. recently reported that binding of Delta/Serrate/Lag-2 (DSL) ligands to heterodimeric Notch on an adjacent cell induces ADAM10-dependent shedding to activate the Notch signaling pathway. Endocytosis of Notch-DSL ligands by DSL ligand expressing cells provides a mechanical force to physically dissociate heterodimeric Notch to induce Notch shedding and signaling (Nichols et al.,2007). Altogether, these findings indicate that various molecular interactions, both inside and outside the cell, regulate ectodomain shedding to specify how and where the protein ectodomains function. However, precisely how cells sense the extracellular environment to regulate ectodomain shedding is not fully understood.
ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- Top of page
- MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- LITERATURE CITED
Ectodomain shedding is a rapid posttranslational process that adds another level of regulation to the expression and function of biologically active molecules. Ectodomain shedding has been implicated in many cellular processes such as cell adhesion, migration, proliferation, differentiation, and death. Consistent with these diverse cellular functions, shedding has also been shown to modulate the onset and progression of several diseases, including Alzheimer's disease (Hooper et al.,2000; Lichtenthaler and Haass,2004), cancer, (Borrell-Pages et al.,2003; Ii et al.,2006; Mochizuki and Okada,2007), infection (Park et al.,2001; Dolnik et al.,2004; Gibot et al.,2004), and various inflammatory disorders (Galonet al.,2000; Li et al.,2002; Xu et al.,2005; Garton et al.,2006).
In Alzheimer's disease, shedding of APP is a key regulatory step in the generation of Aβ peptides that accumulate and form sticky patches in the brains of Alzheimer's patients. Aβ reduces the level of the neurotransmitter acetylcholine, disrupts ion channels essential for nerve excitation, and progressively damages nerve function and signal transmission, leading to a severe impairment of neurological function (Lichtenthaler,2006). Carcinoma cells almost universally show diminished cadherin-mediated intercellular adhesiveness. Thus, shedding of cadherin results in increased invasive behavior and, in fact, soluble cadherin ectodomain levels show a correlation with PSA in prostate cancer and CA 199 in pancreatic adenocarcinoma (Noe et al.,2001; De Wever et al.,2007), suggesting that cadherin ectodomains is a potential diagnostic/prognostic marker.
In tissue injury and inflammation, many immunomodulators are released from the cell surface by ectodomain shedding to function as autocrine or paracrine effectors, indicating that shedding is an important posttranslational mechanism that modulates inflammatory processes. Knock-in mice expressing a nonsheddable construct of TNFRI develop toll-like receptor (TLR)-dependent innate immune hyperreactivity, which enables these mice to become more resistant to bacterial infections, but more susceptible to noninfectious inflammatory disorders such as endotoxic shock, spontaneous hepatitis, TNFα-dependent arthritis, and experimental autoimmune encephalomyelitis (Xanthoulea et al.,2004). In this section, we will highlight the physiological functions of ectodomain shedding in lung development and disease.
Ectodomain Shedding in Lung Development
Peschon et al. generated mice expressing TACE/ADAM17 lacking the Zn++ binding catalytic domain (taceΔZn/ΔZn). The taceΔZn/ΔZn mice exhibit dysgenesis of epithelial cells in multiple organs such as cornea, intestine, lung, thyroid, parathyroid, and skin, and show late embryonic or perinatal lethality (Peschon et al.,1998). The taceΔZn/ΔZn mice also show abnormal lung architecture, such as impaired airway branching, aberrant epithelial cell proliferation and differentiation, and delayed vasculogenesis. Histological examination of taceΔZn/ΔZn embryos on E17.5 shows that the bronchioles are lined by disorganized epithelium with variable hypercellularity, segmental stratification, and increased nuclear to cytoplasmic ratio. Notably, the hypoplastic lung phenotype can be rescued by exogenous soluble TNFα, EGF, or TGFα (Zhao et al.,2001a,b), but the expression level of TGFα is not affected in taceΔZn/ΔZn mice, suggesting that the pathologies are strictly caused by the absence of TACE/ADAM17-mediated shedding of these cytokines and growth factors. Moreover, the phenotypes of taceΔZn/ΔZn mice are similar to those of the TGFα null mice. Strong TACE/ADAM17 expression is detected as early as E12, primarily on epithelial cell surfaces. At E16.5, TACE/ADAM17 is ubiquitously expressed on both lung epithelial and mesenchymal cells, but at E18, the expression in mesenchymal cells is significantly reduced. Collectively, these observations suggest that TACE/ADAM17-mediated ectodomain shedding of several growth factors and cytokines is essential for normal epithelial cell proliferation and differentiation, branching morphogenesis, and vasculogenesis in the lung.
Ectodomain Shedding in Lung Injury and Inflammation
Ectodomain shedding of several cell surface molecules has been linked to the pathogenesis of inflammatory lung diseases. In bleomycin-induced acute lung injury in mice, shedding of syndecan-1 by MMP-7 generates a CXC chemokine gradient that guides the transepithelial migration of neutrophils into the alveolar compartment (Li et al.,2002). In this mechanism, injury caused by bleomycin induces the expression of the CXC chemokine KC (CXCL1, mouse functional homolog of human IL-8) and MMP-7. Newly synthesized KC binds to the heparan sulfate glycosaminoglycans of cell surface syndecan-1, and shedding of the syndecan-1 ectodomain-KC complex by MMP-7 into the alveolar space generates a CXC chemokine gradient across the alveolar epithelial border. The observations that both syndecan-1 and MMP-7 null mice show increased accumulation of neutrophils in the perivascular interstitial space, and significantly reduced neutrophils in the alveolar compartment underscore the importance of this mechanism in coordinating inflammation and confining inflammation to specific sites of tissue injury. Interestingly, though MMP-7 null mice are protected, syndecan-1 null mice show enhanced lung damage and lethality in bleomycin-induced acute lung injury. These data suggest that syndecan-1 ectodomains have additional protective functions in the progression of bleomycin-induced acute lung injury downstream of its shedding by MMP-7.
Shedding of syndecan-1 also plays a protective role in allergic lung inflammation (Xu et al.,2005). Intranasal challenge of mice with Aspergillus spp. culture filtrates induces features of allergic lung inflammation, such as increased airway hyperresponsiveness, and Th2 cell homing to the lung. Airway allergen challenge activates syndecan-1 shedding, and syndecan-1 ectodomains bind to and inhibit the CC chemokines, CCL7, CCL11, and CCL17, to recruit Th2 cells into the lung. Consistent with this mechanism, syndecan-1 null mice show exaggerated airway hyperresponsiveness, glycoprotein hypersecretion, eosinophilia, and Th2 responses in the lung relative to wild-type mice, and airway administration of purified syndecan-1 ectodomains or heparan sulfate rescues allergen-challenged syndecan-1 null mice from these inflammatory phenotypes. These data suggest that syndecan-1 suppresses allergic lung inflammation by directly inhibiting CC chemokine-induced Th2 cell homing in a heparan sulfate-dependent manner.
Several studies have shown that bacterial pathogens subvert ectodomain shedding to enhance their virulence in the lung. For example, lipoteichoic acid released from the cell wall of S. aureus stimulates ADAM-10 mediated shedding of HB-EGF ectodomains, which activate the EGF receptor to induce mucin overexpression and subsequent airflow obstruction in chronic lung infections (Lemjabbar and Basbaum,2002). Streptolysin O, a virulence factor toxin secreted by GAS, stimulates the ectodomain shedding of L-selectin (Walev et al.,2000), IL-6R (Walev et al.,1996) and CD14 (Walev et al.,1996), suggesting that streptolysin O-induced shedding modulates host defenses against GAS infections. P. aeruginosa enhances syndecan-1 shedding by activating the endogenous shedding mechanism through its virulence factor LasA (Park et al.,2000), and syndecan-1 ectodomains promote P. aeruginosa lung pathogenesis by inhibiting several host defense mechanisms and dysregulating the host inflammatory response to infection (Park et al.,2001). The physiological significance of this mechanism is underscored by the observations that syndecan-1 null mice resist intranasal P. aeruginosa lung infection compared to wild-type mice, and intranasal administration of syndecan-1 ectodomain or heparan sulfate restores bacterial virulence in the lung (Park et al.,2001). Interestingly, S. aureus and S. pneumoniae, but not other Gram-positive and Gram-negative bacteria, also enhance syndecan-1 shedding (Park et al.,2004; Chen et al.,2007) and syndecan-1 null mice resist lung infection caused by these major lung bacterial pathogens. These findings suggest that bacterial pathogens with the capacity to enhance syndecan-1 ectodomain shedding do so to promote their pathogenesis by dysregulating the host inflammatory response to infections.
Ectodomain shedding of CD44 modulates the activation and recruitment of several leukocytes. Increased levels of CD44 ectodomain are detected in eosinophilic pneumonia (Katoh et al.,1999), and CD44 null mice show a more pronounced inflammatory response in E. coli-induced pneumonia relative to wild-type mice (Wang et al.,2002). Interestingly, CD44 deletion does not affect pneumococcal pneumonia, suggesting that CD44 is selectively used in the host defense against Gram-negative pneumonia. CD44 null mice also show exaggerated inflammation following bleomycin-induced lung injury, characterized by impaired clearance of apoptotic neutrophils, persistent accumulation of hyaluronan fragments at the site of tissue injury, and impaired activation of TGFβ (Teder et al.,2002). Thus, in contrast to the shedding of syndecan-1, CD44 shedding apparently plays a protective role in both infectious and noninfectious lung injury and inflammation.
- Top of page
- MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- LITERATURE CITED
A wide variety of cell surface proteins are proteolytically cleaved to release their ectodomains into the extracellular milieu. Ectodomain shedding is an important posttranslational modification that adds diversity to the function of cell surface molecules. Ectodomain shedding rapidly downregulates the expression of cell surface proteins, and liberates biologically active soluble ectodomains that can function in an autocrine or paracrine manner. Once released, protein ectodomains exhibit functions similar to or distinct from its cell surface counterpart. Furthermore, recent studies have shown that some pathogens subvert ectodomain shedding to promote their infection. Regulated shedding is typically a mechanism that modulates cellular processes, such as adhesion, migration and proliferation, and assures the correct functioning of development and inflammation. Thus, dysregulation or lack of shedding results in diverse pathologies such as inflammatory lung injury, infection, cancer, and Alzheimer's disease.
Studies during the last two decades have revealed many mechanistic features of ectodomain shedding. Some are common, whereas others are specific to certain substrates. In general, ectodomain shedding is dependent on PKC and metalloproteinase activities. However, PKC isozymes selectively regulate the shedding of certain protein ectodomains, and numerous metalloproteinases can function as sheddases, though available data suggest that TACE/ADAM17 and ADAM10 are the primary sheddases for most ectodomains. Furthermore, several other signaling factors and modifiers, such as PTKs, MAP kinases, calmodulin, BiP and ARTS-1, are selectively used to regulate the shedding of certain cell surface molecules. In addition, cellular processes affecting the recruitment, activation, or polarized secretion of sheddases or substrates can also influence shedding, adding to the complexity of the shedding mechanism. Future studies directed at defining how these regulatory factors and processes coordinate ectodomain shedding should provide mechanistic insights into how cells utilize ectodomain shedding to modulate diverse pathophysiological processes.
- Top of page
- MECHANISTIC FEATURES OF ECTODOMAIN SHEDDING
- ECTODOMAIN SHEDDING IN LUNG DEVELOPMENT AND DISEASES
- LITERATURE CITED
- 2004. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172: 6362–6372. , , , , , , , , , , , , , , .
- 2006. TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin. FASEB J 20: 1939–1941. , , , , , .
- 1998. Blockade of growth hormone receptor shedding by a metalloprotease inhibitor. Endocrinology 139: 1927–1935. , , , , , , , .
- 1996. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271: 11376–11382. , , , , , .
- 1997. Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem 272: 17160–17165. , , .
- 1995. Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism. JCell Biol 128: 433–441. , .
- 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35–40. , , , , , , , , , , , , , , , , , .
- 2005. Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol Cell Neurosci 29: 82–96. , , , , , .
- 2001. Inhibition of the membrane fusion machinery prevents exit from the TGN and proteolytic processing by furin. FEBS Lett 505: 118–124. , , , .
- 1994. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol 152: 1314–1322. , .
- 1991. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147: 4398–4401. , , , , .
- 1999. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci 112 (Pt 16): 2667–2675. , , , , .
- 2004. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost 91: 951–958. , , , , , , .
- 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729–733. , , , , , , , , , , , , , , , , , , , .
- 2005. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. J Immunol 175: 1239–1247. , , , .
- 2003. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22: 1114–1124. , , , , .
- 2003. Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem 278: 25933–25939. , , , , , , , , .
- 1992. The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF alpha into soluble growth factor. Cell 71: 1157–1165. , , .
- 1989. Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors. Cell 56: 691–700. , , , , , , .
- 1994. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem 269: 32488–32496. , , , .
- 2006. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16: 488–501. , , , , , , .
- 2003. Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J Biol Chem 278: 1549–1560. , , , , , , .
- 1998. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765–27767. , , , , , , , , , .
- 2001. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 20: 6277–6287. , , , , , , .
- 2007. Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor. J Biol Chem 282: 159–167. , , , , .
- 1994. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762. , , , , , , , .
- 1991. Shedding of transferrin receptor from rat reticulocytes during maturation in vitro: soluble transferrin receptor is derived from receptor shed in vesicles. Blood 78: 2444–2450. , , .
- 2006. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem 281: 31408–31418. , , , , , , , , , .
- 2003. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 278: 32801–32809. , , , , , .
- 1996. Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease. J Biol Chem 271: 4545–4552. , , , , , .
- 1999. Interleukin-6 receptor shedding: a possible role for members of the ADAM family. Biochem Soc Trans 27: 224–228. , , .
- 1993. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation. J Immunol 151: 6882–6890. , , , .
- 2002. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 110: 515–526. , , , , , , , , .
- 2003a. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 278: 28677–28685. , , , .
- 2003b. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 171: 6814–6819. , , , .
- 2007. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 24: 685–697. , , , , , , .
- 1997. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. J Cell Biol 138: 747–758. , , , , .
- 1998. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem 69: 143–153. , , , , , .
- 2004. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175–2184. , , , , , , , , .
- 1997. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272: 26761–26768. , , , , , , .
- 1990. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248: 1122–1124. , , , , , , , .
- 2005. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280: 19543–19550. , , , , , .
- 1999. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J 18: 6962–6972. , .
- 2006. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 281: 14533–14536. , , .
- 2002. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21: 5213–5223. , , , .
- 2000. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148: 811–824. , , , , .
- 2003. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 278: 30469–30477. , , , .
- 2002. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J 21: 5026–5035. , , , , , , , , , , .
- 2007. Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts. FEBS Lett 581: 5743-5750. , , , , , , , , , , , , .
- 2000. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12: 479–486. , , , , .
- 2004. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 15: 678–687. , , , , , .
- 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993–38001. , , , , , , .
- 2003. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278: 37459–37464. , , , , , , , .
- 2006. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 79: 1105–1116. , , .
- 2002. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem 277: 45898–45903. , , , .
- 1994. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555–557. , , , , , , , , , , Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K.
- 1995. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 57: 774–777. , , , , , , , , , , Gordon LJ, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K.
- 1999. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J Biol Chem 274: 28828–28835. , , , , .
- 2004. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 200: 1419–1426. , , , , , , , .
- 2007. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol 179: 4065–4073. , , , , , , , , , .
- 2005. The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect Immun 73: 1295–1303. , , , .
- 2000. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 275: 15490–15497. , , , , , .
- 1994. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci USA 91: 9170–9174. , , , .
- 2000. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. JImmunol 165: 6703–6709. , , , , , , , .
- 2004. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 18: 893–895. , , , , , , , , .
- 2000. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105: 143–150. , , , , , .
- 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289: 1360–1365. , , .
- 2005. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112: 812–818. , , , , , , , , , , , .
- 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625–637. , , , , , , , , , , , .
- 2004. Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J Biol Chem 279: 31149–31156. , , , .
- 1998. Mutation of proline 211 reduces shedding of the human p75 TNF receptor. J Immunol 160: 2478–2487. , .
- 1998. Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 9: 1589–1601. , , , .
- 2007. Ectodomain shedding of receptor activator of NF-κB ligand. Adv Exp Med Biol 602: 15–21. , .
- 2000. The role of proteolysis in Alzheimer's disease. Adv Exp Med Biol 477: 379–390. , , , .
- 2007a. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18: 176–188. , , , , , , , , , .
- 2007b. Cell surface colony-stimulating factor 1 can be cleaved by TNF-alpha converting enzyme or endocytosed in a clathrin-dependent manner. J Immunol 179: 6715–6724. , , , , , , , , , , , , .
- 2005. Neural cell adhesion molecule function is regulated by metalloproteinase-mediated ectodomain release. J Neurosci Res 80: 826–837. , , , .
- 2005. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30: 413–422. , , , , .
- 2003. Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem 278: 36264–36268. , , , , , .
- 2006. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231: 20–27. , , , , .
- 2001. PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 15: 362–372. , , , .
- 2002. The cytoplasmic tail of L-selectin interacts with members of the ezrin-radixin-moesin (ERM) family of proteins: cell activation-dependent binding of moesin but not ezrin. J Biol Chem 277: 2321–2329. , , , .
- 2004. Mutagenesis of the ezrin-radixin-moesin binding domain of L-selectin tail affects shedding, microvillar positioning, and leukocyte tethering. J Biol Chem 279: 33263–33272. , , , , , .
- 1998. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17: 7260–7272. , , , , , , , , , , .
- 2003. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22: 2704–2716. , , , , , , .
- 2001. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci USA 98: 13693–13698. , , , , , .
- 1999. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 189: 599–604. , , , , , .
- 1996. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 183: 1587–1602. , .
- 1998. Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism. Cell 92: 809–818. , , , , .
- 1999. Overexpression of CD44 on alveolar eosinophils with high concentrations of soluble CD44 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Allergy 54: 1286–1292. , , , , , , , .
- 2002. Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2. J Biol Chem 277: 38494–38502. , , , .
- 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA 89: 10277–10281. , , , .
- 2004. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 279: 52132–52140. , , , , , , , .
- 2006. Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem 281: 6826–6840. , , , , , .
- 2003. Acquisition of stcE, a C1 esterase inhibitor-specific metalloprotease, during the evolution of Escherichia coli O157:H7. J Infect Dis 187: 1907–1914. , , , , .
- 2003. The notch ligands, jagged and delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem 278: 34427–34437. , .
- 2003. Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process. J Biol Chem 278: 45255–45268. , , , .
- 2007. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis. Infect Immun 75: 3848–3858. , , , , , , .
- 2002. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8: 41–46. , .
- 1990. Mechanism of formation of human IgE-binding factors (soluble CD23): III. Evidence for a receptor (Fc epsilon RII)-associated proteolytic activity. J Exp Med 172: 693–700. , , , , .
- 2007. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26: 494–504. , , , , , , , , , , , , .
- 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111: 635–646. , , , .
- 2006. Ectodomain shedding of the amyloid precursor protein: cellular control mechanisms and novel modifiers. Neurodegener Dis 3: 262–269. .
- 2004. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 113: 1384–1387. , .
- 1991. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6: 639–643. , .
- 1999. Regulation of human ADAM 12 protease by the prodomain. Evidence for a functional cysteine switch. J Biol Chem 274: 13427–13433. , , , , .
- 2001. Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10. J Neurochem 76: 1532–1539. , , , , , .
- 1998. Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J Biol Chem 273: 26236–26247. , , .
- 1999. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274: 13613–13618. , , , , , , , , .
- 1999. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1). A nonpharmacological explanation for inhibition of TNF-mediated activation. J Biol Chem 274: 13643–13649. , , .
- 2005. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 102: 9182–9187. , , , , , , , , .
- 2007. Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2. J Biol Chem 282: 30509–30517. , , , , , , .
- 1991. “Secretase,” Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem Biophys Res Commun 179: 1670–1676. , , , , .
- 2001. The cytoplasmic domain of L-selectin participates in regulating L-selectin endoproteolysis. J Immunol 167: 1617–1623. , , , .
- 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 1: 298–304. , , , , .
- 2001. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 28: 22–28. , , , , , .
- 2003. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278: 38829–38839. , , , , , , , , , , .
- 2003. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162: 1831–1843. , , .
- 2001. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661–673. , , , , , , , , , , .
- 1995. Mutational analysis of the membrane-proximal cleavage site of L-selectin: relaxed sequence specificity surrounding the cleavage site. J Exp Med 182: 549–557. , , .
- 1994. Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: activation of pro-HGF. Biochem Biophys Res Commun 198: 1161–1169. , , , , , .
- 2007. ADAMs in cancer cell proliferation and progression. Cancer Sci 98: 621–628. , .
- 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218–220. , , , , , , , , , , Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA.
- 2004. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 173: 1681–1688. , , , .
- 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733–736. , , , , , , , , , , , , , , , , , , , , , , , , .
- 1994. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 152: 4958–4968. , , , , , , , .
- 2000. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 20: 715–720. , , , , , , .
- 2004. Cell–matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165: 893–902. , , , , , , , , .
- 2001. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114: 1213–1220. , , , .
- 2004. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 279: 16083–16090. , , , , , .
- 2006. Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein. J Biol Chem 281: 7583–7594. , , , , , , .
- 2007. DSL ligand endocytosis physically dissociates Notch1 heterodimers before activating proteolysis can occur. J Cell Biol 176: 445–458. , , , , , .
- 2001. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114: 111–118. , , , , , , , , .
- 2004. Ectodomain shedding of SHPS-1 and its role in regulation of cell migration. J Biol Chem 279: 27878–27887. , , , , , , .
- 2004. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol 200: 2–10. , , .
- 1997. Kuzbanian controls proteolytic processing of notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 90: 271–280. , .
- 1992. Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. J Biol Chem 267: 24028–24033. , , , , .
- 2004. Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J Biol Chem 279: 251–258. , , , , , .
- 2001. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411: 98–102. , , , .
- 2000. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J Biol Chem 275: 3057–3064. , , , , , .
- 1998. An essential role for ectodomain shedding in mammalian development. Science 282: 1281–1284. , , , , , , , , , , , , , , , , , , .
- 2003. Molecular mechanisms of L-selectin-induced co-localization in rafts and shedding [corrected]. Biochem Biophys Res Commun 300: 563–569. , , , , , , .
- 1990. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172: 599–607. , .
- 1999. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9: 1441–1447. , , , , .
- 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884–888. , , , , , , .
- 2002. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inflammatory stimuli up-regulate secretion of the soluble GM-CSF receptor in human monocytes: evidence for ectodomain shedding of the cell surface GM-CSF receptor alpha subunit. J Immunol 169: 5679–5688. , , , , , , , , , .
- 2005. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 280: 14462–14468. , , , .
- 1996. Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 319 (Pt 1): 39–47. , , , , , .
- 2005. ADAM10 cleavage of N-cadherin and regulation of cell–cell adhesion and beta-catenin nuclear signalling. EMBO J 24: 742–752. , , , , , , .
- 2001. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 106: 105–116. , , , , , , , , , , .
- 2000. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275: 10379–10387. , , , .
- 1995. In vitro processing of human tumor necrosis factor-alpha. J Biol Chem 270: 23688–23692. , , , , , , , .
- 1999. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274: 3531–3540. , , , , , , , , , .
- 1999. Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice. J Biol Chem 274: 10511–10516. , , , , , .
- 2004. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769–779. , , , , , , , , .
- 2005. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280: 1826–1837. , , , , , , , .
- 2004. Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensin-converting enzyme. J Biol Chem 279: 40227–40236. , , , , , .
- 2000. Specific cellular proteins associate with angiotensin-converting enzyme and regulate its intracellular transport and cleavage-secretion. J Biol Chem 275: 23253–23258. , .
- 2001. The bacterial toxin toolkit. Nat Rev Mol Cell Biol 2: 530–537. , .
- 1999. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 112 (Pt 21): 3603–3617. , .
- 2001. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 276: 14665–14674. , , .
- 1989. Suppression of human leukocyte tumor necrosis factor secretion by the serine protease inhibitor p-toluenesulfonyl-L-arginine methyl ester (TAME). J Immunol 143: 168–173. .
- 1999. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 64: 1326–1335. , , , , , , .
- 2006. CD21 and CD62L shedding are both inducible via P2X7Rs. Int Immunol 18: 1171–1178. , , .
- 2001. Antibody-induced shedding of CD44 from adherent cells is linked to the assembly of the cytoskeleton. J Immunol 167: 123–131. , , , , .
- 2007. Ectodomain shedding of neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, by TIMP-2- and TIMP-3-sensitive proteolysis. J Neurochem 102: 1561–1568. , , , , , , , , , .
- 2005. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res 67: 39–49. , , , , , , , , .
- 1992. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 89: 6075–6079. .
- 1990. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248: 492–495. , , , , .
- 1995. Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor. J Biol Chem 270: 8337–8344. , , , , .
- 2005. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132: 3923–3933. , , , , , .
- 1992. Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region. EMBO J 11: 897–907. , , , , , , , , .
- 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272: 14713–14720. , , .
- 2004. Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem 279: 51601–51611. , , , , , , .
- 2002. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 277: 12838–12845. , , , , , , , , , , .
- 1997. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. JBiol Chem 272: 31730–31737. , , , , .
- 2007. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67: 2030–2039. , , , , , , , .
- 1998. Downregulation of Fas ligand by shedding. Nat Med 4: 31–36. , , , .
- 2002. Ectodomain shedding of nectin-1alpha by SF/HGF and TPA in MDCK cells. Biochem Biophys Res Commun 299: 472–478. , , , , , .
- 1996. Length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. Biochemistry 35: 8226–8233. , , .
- 2002. Resolution of lung inflammation by CD44. Science 296: 155–158. , , , , , , , .
- 2001. Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells. Biochem J 358: 193–200. , , , .
- 2003. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 278: 3386–3394. , , .
- 1994. Human macrophage colony-stimulating factor is expressed at and shed from the cell surface. Blood 84: 2182–2188. , , , , , .
- 2004. The shed ectodomain of type XIII collagen affects cell behaviour in a matrix-dependent manner. Biochem J 380: 685–693. , , .
- 2007. Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment. J Biol Chem 282: 27424–27435. , , , , , , , .
- 2004. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279: 7721–7733. , , .
- 1996. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun 64: 3646–3651. , , , .
- 1997. Cleavage of beta 4 integrin by matrilysin. Exp Cell Res 236: 341–345. , , , .
- 2004. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 172: 4324–4331. , , , , , , .
- 2000. Streptolysin O-permeabilized granulocytes shed L-selectin concomitantly with ceramide generation via neutral sphingomyelinase. J Leukoc Biol 68: 865–872. , , , .
- 1996. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci USA 93: 7882–7887. , , , , .
- 2002. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am J Pathol 161: 2219–2228. , , , , .
- 2006. Cytoplasmic domain phosphorylation of heparin-binding EGF-like growth factor. Cell Struct Funct 31: 15–27. , , , , , .
- 2004. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem 279: 4241–4249. , , , , , , , , .
- 2003. Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice. Cancer Res 63: 6547–6555. , , , .
- 2006. A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration. J Biol Chem 281: 23824–23829. , , , , .
- 1989. The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell 56: 495–506. , , , , , , , .
- 2007. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J Cell Sci 120: 1944–1952. , , , , .
- 1997. TNF-alpha and IL-1 upregulate membrane-bound and soluble E-selectin through a common pathway. J Surg Res 73: 107–112. , , , , , .
- 2004. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200: 367–376. , , , , , , , .
- 2005. Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 174: 5758–5765. , , , .
- 1999. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 93: 1969–1979. , , , , , .
- 2002. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16: 307–323. , ,Jr. , .
- 2001. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 15: 303–305. , , , , , , .
- 2001a. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 232: 204–218. , , , , , , .
- 2001b. Abrogation of tumor necrosis factor-alpha converting enzyme inhibits embryonic lung morphogenesis in culture. Int J Dev Biol 45: 623–631. , , , .
- 2001c. Regulation of membrane metalloproteolytic cleavage of L-selectin (CD62l) by the epidermal growth factor domain. J Biol Chem 276: 30631–30640. , , , .